ArticleBMC women's health2026
The relationship between serum galectin-3 level and echocardiographic findings in patients with polycystic ovary syndrome.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimIn the our study, we examined the relationship between galectin-3 levels and global longitudinal strain (GLS) and aortic intima-media thickness (A-IMT) in patients with polycystic ovary syndrome (PCOS). We evaluated the potential of this molecule as a biomarker in the early stages of atherosclerosis and heart failure. MATERIAL AND
methodA total of 80 participants, 40 newly diagnosed PCOS patients and 40 healthy controls, were included in the Health Sciences University Adana City Training and Research Hospital between 01.06.2021 and 31.03.2022. Galectin-3 level was measured by using Human galectin-3 kits and Enzyme-Linked Immuno Sorbent Assay method. A-IMT and GLS measurements were performed by using ultrasonography and echocardiography.
resultsWhen both study groups were evaluated, a statistically significant difference was found between the PCOS patient and the control groups in terms of blood glucose (93.6 ± 9.82 mg/dL to 87.7 ± 8.42 mg/dL; p = 0.006) HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) Index (2.55 ± 0.49 to 2.05 ± 0.61; p < 0.001), galectin-3 (13.7 ± 0.98 ng/mL to 12.2 ± 2.08 ng/mL; p < 0.001), A-IMT (1.41 ± 0.008 mm to 1.25 ± 0.16 mm; p < 0.001), and GLS (-16.7 ± 1.75% to -18.8 ± 1.37%; p < 0.001) values A correlation analysis was conducted, resulting in the identification of a robust association between galectin-3 levels and GLS (r = 0.747, p < 0.001). Additionally, weaker yet statistically significant correlations were observed between galectin-3 levels and A-IMT (r = 0.327, p = 0.006) and HOMA-IR (r = 0.446, p < 0.001). Multivariate analysis revealed that GLS was the only independent predictor of galectin-3 levels (B = 0.395; p < 0.001). Conversely, A-IMT and HOMA-IR were not significant predictors (p = 0.340 and p = 0.887, respectively).
conclusionGalectin-3 levels were significantly associated with markers of subclinical atherosclerosis and early cardiac dysfunction in patients with PCOS. Galectin-3 demonstrated potential utility as a biomarker for the early identification of subclinical atherosclerosis and heart failure risk in this population. Notably, this study is the first to evaluate the association of galectin-3 with both A-IMT and GLS in patients with PCOS, providing novel insights into their cardiovascular risk profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.